Valeant Pharmaceuticals Articles
Valeant to commercialize Intendis products in UK
16 October 2006
Valeant launches new chemotherapy management guide
28 August 2006
Valeant launches Zelapar in USA
24 July 2006
Valeant 1st-qtr 2006 loss deepens to $6.4M
15 May 2006
GMP standards soon for Russian drug firms
3 April 2006
Strong data for Metabasis' HBV drug
27 March 2006
Non-approvable letter for Valeant's Cesamet labeling
9 January 2006
Valeant to buy Infergen from InterMune
5 December 2005
Sun Pharma to acquire stake in ICN group of Hungary
15 August 2005
Valeant to develop Viramidine in Japan
1 August 2005
Valeant sales rise 22%
16 May 2005
Valeant's HCV drug gives good Phase II performance
26 April 2005
Valeant competes Xcel Pharma buy
7 March 2005
Valeant to acquire Xcel Pharma
7 February 2005
Valeant moves closer to Zelapar approval
17 January 2005
Valeant promotes Timothy Tyson to CEO
10 January 2005
Valeant to sell one Mexican facility
10 January 2005
Valeant and Alliance raise neurology presence
22 November 2004
Amarin and Valeant sign settlement deal
4 October 2004
Valeant gets further rights to Tasmar
20 September 2004
UPDATE: Valeant sees net loss climb 177% for 2nd-qtr
16 August 2004
Valeant sees net loss climb 177% for 2nd-qtr
16 August 2004
Valeant sells Czech manufacturing operations
9 August 2004
Metabasis initiates Ph II remofovir trial
9 August 2004
Amarin Corp sees revenues plunge
5 April 2004
Stock Commentary - New York
15 March 2004
Valeant sees 4th-qtr 2003 revenues slide
15 March 2004
Valeant buys Amarin unit in $38M deal
23 February 2004
Russian billionaire Abramovich to sell ICN stake?
8 December 2003
Stock Commentary - New York
24 November 2003
ICN changes name; reports 3rd-qtr results
17 November 2003
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
